IP Library › Granted Patent US 12,461,112
Granted Patent B2
US 12,461,112 · App. 18/329,892 · Granted Nov 4, 2025

Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma

Inventors: Timothy E. Van Meter (Richmond, VA); Nazanin Mirshahi (Richmond, VA)
Assignee: Brainbox Solutions, Inc.
G01N33/6896A61B5/4064G01N2800/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,461,112
App. No.
18/329,892
Granted
Nov 4, 2025
Kind
B2
Abstract

Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of brain injuries, especially mild traumatic brain injury (mTBI) or concussion, are based upon detection of changes in levels of certain protein biomarkers in a subject undergoing testing, or upon detection of changes in levels of certain protein biomarkers in conjunction with neuroimaging analyses to detect changes in vascular or blood brain barrier (BBB) permeability in the brain, or to detect damage to fiber tracts in the brain, in which changes in biomarker levels correlate with detection of changes in BBB permeability or in brain fiber tract or white matter damage in a subject with brain injury such as mTBI or concussion.

Claims (25)

1 . A method of measuring one or more biomarkers and neuroimaging one or more fiber tracts in the brain of an individual suspected to have brain injury, the method comprising the steps of:

a. measuring levels of one or more brain specific protein biomarkers selected from Neurogranin (NRGN) and/or Glial Fibrillary Acidic Protein (GFAP) in a biological sample obtained from the individual;

b. neuroimaging the individual to visualize fiber tracts in the brain when the levels of one or more of the biomarker proteins in the sample are altered relative to respective control levels using a specialized neuroimaging technique; and

c. detecting changes in one or more fiber tracts in the brain relative to a control.

2 . The method of claim 1 , wherein the biological sample is selected from one or more of blood, serum, plasma, saliva, or cerebrospinal fluid (CSF).

3 . The method of claim 1 , further comprising:

d. measuring levels of one or more brain specific protein biomarkers selected from Aldolase C (ALDOC), Brain Derived Neurotrophic Factor (BDNF), Neuron Specific Enolase (NSE), Oligodendrocyte Myelin Glycoprotein (OMG), and Synuclein Beta (SNCB) in the biological sample; and

e. detecting increases in the levels of one or more of the ALDOC, GFAP, NRGN, NSE, and OMG biomarkers relative to respective control levels, or decreases in the levels of one or more of the BDNF and SNCB biomarkers relative to control levels.

4 . The method of claim 1 , wherein the changes detected in one or more fiber tracts in the brain comprise changes in the inferior frontooccipital fasciculus (IFOF) tract.

5 . The method of claim 1 , wherein the specialized neuroimaging technique comprises contrast MRI, Diffusion Tensor Imaging MRI (DTI-MRI) or Dynamic Contrast Enhanced MRI (DCE-MRI).

6 . The method of claim 1 , wherein the subject suffers from repetitive sub-concussive injury as indicated by the changes in the one or more fiber tracts in the brain.

7 . The method of detecting of claim 1 , wherein if the changes to the fiber tracts in the brain are correlated with the alterations in the levels of the one or more biomarker proteins, the subject should not return to work or play.

8 . The method of claim 1 , further comprising:

d. measuring levels of one or more brain specific protein biomarkers selected from Aldolase C (ALDOC), Brain Derived Neurotrophic Factor (BDNF), Neuron Specific Enolase (NSE), and Oligodendrocyte Myelin Glycoprotein (OMG) in the biological sample; and

e. detecting increases in the levels of one or more of the ALDOC, GFAP, NRGN, NSE, or OMG biomarkers relative to respective control levels or a decrease in the levels of the BDNF biomarker relative to control levels.

9 . The method of claim 8 , wherein the one of more biomarkers comprise isoforms and/or are post-translationally modified.

10 . The method of claim 1 , wherein further comprising:

d. measuring levels of one or more brain specific protein biomarkers selected from Aldolase C (ALDOC), Neuron Specific Enolase (NSE), Oligodendrocyte Myelin Glycoprotein (OMG), and Synuclein Beta (SNCB) in the biological sample; and

e. detecting increases in the levels of one or more of the ALDOC, NRGN, or NSE biomarkers relative to control levels, or a decrease in the levels of the SNCB biomarker relative to control levels.

11 . The method of claim 1 , wherein the individual has or is suspected of having mild traumatic brain injury (mTBI) or a concussion.

12 . The method of claim 1 , wherein the one of more biomarkers comprise isoforms and/or are post-translationally modified.

13 . The method of claim 1 , wherein further comprising:

d. measuring levels of one or more brain specific protein biomarkers selected from Intracellular Adhesion Molecule 5 (ICAM5) and Metallothionein 3 (MT3) in the biological sample; and

e. detecting alterations in the levels of one or more of the MT-3 and ICAM-5 biomarkers relative to control levels.

14 . The method of claim 13 , wherein the one of more biomarkers comprise isoforms and/or are post-translationally modified.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2023
From: IMMUNARRAY USA, INC.
To: BRAINBOX SOLUTIONS, INC.
Reel/Frame 064622/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2023
From: VAN METER, TIMOTHY E.; MIRSHAHI, NAZANIN
To: IMMUNARRAY USA, INC.
Reel/Frame 064622/0784 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2023
From: VAN METER, TIMOTHY E.; MIRSHAHI, NAZANIN
To: IMMUNARRAY USA, INC.
Reel/Frame 064622/0815 →
Continuity (4)
Division 16616051
Provisional Application 62532180 · Jul 13, 2017
Provisional Application 62510096 · May 23, 2017
Related Publication 20230314453A1 · Oct 5, 2023
References Cited (99)
US 11761959B2 · Siman · 2023 [cited by applicant]
US 20110082203A1 · Wang · 2011 [cited by applicant]
US 20110177974A1 · Wang · 2011 [cited by applicant]
US 20140045713A1 · Everett · 2014 [cited by applicant]
US 20160178643A1 · Everett et al. · 2016 [cited by applicant]
US 20170023591A1 · Bowser et al. · 2017 [cited by applicant]
US 20230393133A1 · Siman · 2023 [cited by applicant]
CN 103118698A · 2013 [cited by applicant]
WO 2010148391A2 · 2010 [cited by applicant]
WO 2011147981A2 · 2011 [cited by applicant]
WO 2016048488A1 · 2016 [cited by applicant]
WO 2016125148A1 · 2016 [cited by applicant]
Papa et al., J Neurotrauma, 31:1815-1822, (Year: 2014). [cited by examiner]
Bembea et al., Crit Care Med 2015; 43:2202-2211 Oct. 2015. [cited by examiner]
Singh et al., Experimental Neurology, 275:427-435, Jul. 26, 2015. [cited by examiner]
Zoltewicz et al. Biomarker Insights :7, 71-79 (Year: 2012). [cited by examiner]
International Search Report and Written Opinion in International Application No. PCT/US18/33943, dated Sep. 27, 2018. [cited by applicant]
International Preliminary Report in Patentability International Application No. PCT/US18/33943, dated May 23, 2017. [cited by applicant]
Barzo et al., “Magnetic resonance imaging-monitored acute blood-brain barrier changes in experimental traumatic brain injury”, Journal of Neurosurgery, Dec. 1996, pp. 1113-1121, 85(6), Abstract, American Association of … [cited by applicant]
Zhang et al., “Chapter 12 Biomarkers of Traumatic Brain Injury and Their Relationship to Pathology”, Translational Research in Traumatic Brain Injury, 2016, CRC Press/Taylor and Francis Group. [cited by applicant]
Korn et al., “Focal Cortical Dysfunction and Blood-Brain Barrier Disruption in Patients with Postconcussion Syndrome”, Journal of Clinical Neurophysiology, Feb. 2005, 22(1), Lippincott Williams & Willkins. [cited by applicant]
Metting et al. “GFAP and S100B in the acute phase of mild traumatic brain injury”, Neurology, May 1, 2012, 78(18), Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Ne… [cited by applicant]
Kou et al. Combining Biochemical and Imaging Markers to Improve Diagnosis and Characterization of Mild Traumatic Brain Injury in the Acute Setting: Results from a Pilot Study, PLoS One, Nov. 2013, 8(11). [cited by applicant]
Meco C, Arrer E, Oberascher G. 2007. Efficacy of cerebrospinal fluid fistula repair: Sensitive quality control using the beta-trace protein test. Am J Rhinol 21:729-736. [cited by applicant]
Mouser PE, Head E, Ha KH, Rohn TT. 2006. Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol 168:936-46. [cited by applicant]
Mu J, Yang Y, Chen J, Cheng K, Li Q, Wei Y, Zhu D, Shao W, Zheng P, Xie P. 2015. Elevated host lipid metabolism revealed by iTRAQ-based quantitative proteomic analysis of cerebrospinal fluid of tuberculous meningitis pa… [cited by applicant]
Newcombe J, Woodroofe MN, Cuzner ML. 1986. Distribution of glial fibrillary acidic protein in gliosed human white matter. J Neurochem 47:1713-9. [cited by applicant]
Okonkwo Do, Yue JK, Puccio AM, Panczykowski DM, Inoue T, McMahon PJ, Sorani MD, Yuh EL, Lingsma HF, Maas AI and others. 2013. GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospectiv… [cited by applicant]
Osman I, Gaillard O, Meillet D, Bordas-Fonfrede M, Gervais A, Schuller E, Delattre J, Legrand A. 1995. A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. A… [cited by applicant]
Osuna E, Perez-Carceles MD, Luna A, Pounder DJ. 1992. Efficacy of cerebro-spinal fluid biochemistry in the diagnosis of brain insult. Forensic Sci Int 52(2):193-8. [cited by applicant]
Pahari DR, Gu YJ, van Oeveren W, El-Essawi A, Harringer W, Brouwer RM. 2013. Effect of minimized perfusion circuit on brain injury markers carnosinase and brain-type fatty binding protein in coronary artery bypass graft… [cited by applicant]
Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, Brophy GM, Demery JA, Dixit NK, Ferguson I and others. 2012. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate … [cited by applicant]
Pelinka Le, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. 2004a. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 21:1553-61. [cited by applicant]
Pelinka Le, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, Raabe A. 2004b. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 57:1006-12. [cited by applicant]
Pelsers MM, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR and others. 2004. Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and c… [cited by applicant]
Reiber H, Walther K, Althaus H. 2003. Beta-trace protein as sensitive marker for CSF rhinorhea and CSF otorhea. Acta Neurol Scand 108:359-62. [cited by applicant]
Rivett AJ. 1985. Preferential degradation of the oxidatively modified form of glutamine synthetase by intracellular mammalian proteases. J Biol Chem 260:300-5. [cited by applicant]
Rohn TT, Catlin LW, Poon WW. 2013. Caspase-cleaved glial fibrillary acidic protein within cerebellar white matter of the Alzheimer's disease brain. Int J Clin Exp Pathol 6:41-8. [cited by applicant]
Shen S, Loo RR, Wanner IB, Loo J. Addressing the needs of traumatic brain injury with clinical proteomics. Clin Proteomics. Mar. 28, 2014;11(1):11. doi: 10.1186/1559-0275-11-11. [cited by applicant]
Stoevring B, Frederiksen JL, Christiansen M. 2007. CRYAB promoter polymorphisms: influence on multiple sclerosis susceptibility and clinical presentation. Clin Chim Acta 375:57-62. [cited by applicant]
Teunissen CE, Veerhuis R, De Vente J, Verhey FR, Vreeling F, van Boxtel MP, Glatz JF, Pelsers MA. 2011. Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur J Ne… [cited by applicant]
Timmer NM, Herbert MK, Claassen JA, Kuiperij HB, Verbeek MM. 2015. Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged. Neurobiol Aging 36:1271-3. [cited by applicant]
Vadakkan Ki, Mammen T, Wadhwa VS. 2015. Sum of two catalytic activities of the glutamine synthetase enzyme is a blood biomarker for stroke and is optimized for a rapid diagnostic test. Int J Stroke 10:E1-2. [cited by applicant]
Vazquez MD, Sanchez-Rodriguez F, Osuna E, Diaz J, Cox DE, Perez-Carceles MD, Martinez P, Luna A, Pounder DJ. 1995. Creatine kinase BB and neuron-specific enolase in cerebrospinal fluid in the diagnosis of brain insult. … [cited by applicant]
Vermeiren Y, Le Bastard N, Clark CM, Engelborghs S, De Deyn PP. 2011. Serum glutamine synthetase has No. value as a diagnostic biomarker for Alzheimer's disease. Neurochem Res 36:1858-62. [cited by applicant]
Wanner Ina B., et al., Profiling the Injury Signature of Astrocytes for New Neurotrauma Biomarkers. Abstract from The 30th Annual National Neurotrauma Symposium. Jul. 22-25, 2012. Phoenix Arizona. p. A-61. [cited by applicant]
Wanner Ina B., et al., Profiling the Injury Signature of Astrocytes for New Neurotrauma Biomarkers. Poster Presented 2012. Phoenix Arizona. [cited by applicant]
Wijman, C.A.C., et al., Research and Technology in Neurocritical Care. Neurocrit Care. Feb. 2012 ; 16(1): 42-54. [cited by applicant]
Wunderlich MT, Hanhoff T, Goertler M, Spener F, Glatz JF, Wallesch CW, Pelsers MM. 2005. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 252:718-24. [cited by applicant]
Yan X, Liu T, Yang S, Ding Q, Liu Y, Zhang X, Que H, Wei K, Luo Z, Liu S. 2009. Proteomic profiling of the insoluble pellets of the transected rat spinal cord. J Neurotrauma 26:179-93. [cited by applicant]
Yang Z, Wang KK. 2015. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38:364-374. [cited by applicant]
Zhang, Zhiqun, et al., Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products. PLoS ONE 9(3): e92698. [cited by applicant]
Zhao X, Ahram A, Berman RF, Muizelaar JP, Lyeth BG. 2003. Early loss of astrocytes after experimental traumatic brain injury. Glia 44:140-52. [cited by applicant]
Zoltewicz JS, Scharf D, Yang B, Chawla A, Newsom KJ, Fang L. 2012. Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury. Biomark Insights 7:71-9. [cited by applicant]
International Search Report and Written Opinion for PCT/US2016/031043 (WO16179426 Published Nov. 10, 2016). [cited by applicant]
Hulscher et al., “The Diagnostic Value of Brain-Fatty Acid Bidning Protein in Traumatic Brain Injury”, Journal of Neurotrauma, 31:411, Feb. 15, 2014. [cited by applicant]
Kou et al., “Combining Biochemical and Imaging Markers to Improve Diagnosis and Characterization of Mild Traumatic Brain Injury in the Acute Setting: Results from a Pilot Study”, PLOS One, Nov. 2013, vol. 8, Issue 11, e… [cited by applicant]
Arrer E, Meco C, Oberascher G, Piotrowski W, Albegger K, Patsch W. 2002. beta-Trace protein as a marker for cerebrospinal fluid rhinorrhea. Clin Chem 48:939-41. [cited by applicant]
Asaka M, Kimura T, Nishikawa S, Saitoh M, Miyazaki T, Takatori T, Alpert E. 1990. Serum aldolase isozyme levels in patients with cerebrovascular diseases. Am J Med Sci 300(5):291-5. [cited by applicant]
Bachmann-Harildstad G, Stenklev NC, Myrvoll E, Jablonski G, Klingenberg O. 2011. beta-trace protein as a diagnostic marker for perilymphatic fluid fistula: a prospective controlled pilot study to test a sample collectio… [cited by applicant]
Bachmann-Harildstad G. 2008. Diagnostic values of beta-2 transferrin and beta-trace protein as markers for cerebrospinal fluid fistula. Rhinology 46:82-5. [cited by applicant]
Barzo, P, et al. Magnetic resonance imaging-monitored acute blood-brain barrier changes in experimental traumatic brain injury. J Neurosurg 85:1113-1121, 1996. [cited by applicant]
Bourguignat A, Ferard G, Jung G, Klumpp T, Metais p. 1983. Multivariate analysis of plasma enzyme profiles in severe head injury. Clin Chem 29:107-9. [cited by applicant]
Brettschneider J, Riepe MW, Petereit HF, Ludolph AC, Tumani H. 2004. Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus? J Neurol N… [cited by applicant]
Buki, A. et al. (2015) Minor and Repetitive Head Injury. In: Schramm J. (eds) Advances and Technical Standards in Neurosurgery. Advances and Technical Standards in Neurosurgery, vol. 42. Springer, Cham. [cited by applicant]
Chang RY, Etheridge N, Dodd PR, Nouwens AS. 2014. Targeted quantitative analysis of synaptic proteins in Alzheimer's disease brain. Neurochem Int 75:66-75. [cited by applicant]
Chen MH, Hagemann TL, Quinlan RA, Messing A, Perng MD. 2013. Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation. ASN Neuro 5:e00125. [cited by applicant]
Ding B, Xi Y, Gao M, Li Z, Xu C, Fan S, He W. 2014. Gene expression profiles of entorhinal cortex in Alzheimer's disease. Am J Alzheimers Dis Other Demen 29(6):526-32. [cited by applicant]
Feala, Jacob D., et al., Systems Biology Approaches for Discovering Biomarkers for Traumatic Brain Injury Journal of Neurotrauma. Jul. 2013, 30(13): 1101-1116. [cited by applicant]
Florez G, Cabeza A, Gonzalez JM, Garcia J, Ucar S. 1976. Changes in serum and cerebrospinal fluid enzyme activity after head injury. Acta Neurochir (Wien) 35(1-3):3-13. [cited by applicant]
Gao WM, Chadha MS, Berger RP, Omenn GS, Allen DL, Pisano M, Adelson PD, Clark RS, Jenkins LW, Kochanek PM. 2007. A gel-based proteomic comparison of human cerebrospinal fluid between inflicted and non-inflicted pediatri… [cited by applicant]
Hausdoerfer J, Heller W, Schinkmann L. 1975. Biochemical and biophysical changes in guinea pigs after acute head injury. Resuscitation 4(2):77-86. [cited by applicant]
Hicks, RR, et al. Mild Experimental Brain Injury in the Rat Induces Cognitive Deficits Associated with Regional Neuronal Loss in the Hippocampus. 1993 J of Neurotrauma 10(4):405-414. [cited by applicant]
Ichkova, Aleksandra and Badaut, Jerome. New biomarker stars for traumatic brain injury. Journal of Cerebral Blood Flow & Metabolism. 2017, vol. 37(10) 3276-3277. [cited by applicant]
Jung G, Morel J, Bourguignat A, Ferard G. 1983. Modifications of plasma enzyme activities after severe head injury; evaluation of prognosis using multivariate methods. Clin Chim Acta 127(3):365-71. [cited by applicant]
Kay AD, Day SP, Nicoll JA, Packard CJ, Caslake MJ. 2003. Remodelling of cerebrospinal fluid lipoproteins after subarachnoid hemorrhage. Atherosclerosis 170:141-6. [cited by applicant]
Ke K, Li L, Rui Y, Zheng H, Tan X, Xu W, Cao J, Xu J, Cui G, Xu G and others. 2013. Increased expression of small heat shock protein alphaB-crystallin after intracerebral hemorrhage in adult rats. J Mol Neurosci 51:159-… [cited by applicant]
Klun B. 1974. Spinal fluid and blood serum enzyme activity in brain injuries. J Neurosurg 41(2):224-8. [cited by applicant]
Koh, DW, Dawson TM, Dawson VL. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res. Jul. 2005;52(1):5-14. [cited by applicant]
Koh, L., et al. Development of cerebrospinal fluid absorption sites in the pig and rat: connections between the subarachnoid space and lymphatic vessels in the olfactory turbinates. Anat Embryol (Berl). Aug. 2006;211(4)… [cited by applicant]
Koh, Phil-Ok, Melatonin prevents down-regulation of astrocytic phosphoprotein PEA-15 in ischemic brain injury. J of Pineal Research, vol. 51, Issue 4, Nov. 2011, pp. 381-386. [cited by applicant]
Koh, Phil-Ok. 2012a. Ferulic acid prevents the cerebral ischemic injury-induced decreases of astrocytic phosphoprotein PEA-15 and its two phosphorylated forms. Neurosci Lett 511:101-5. [cited by applicant]
Koh, Phil-Ok. 2012b. Nicotinamide attenuates the decrease of astrocytic phosphoprotein PEA-15 in focal cerebral ischemic injury. J Vet Med Sci 74:377-80. [cited by applicant]
Koh, Phil-Ok. Gingko biloba Extract (EGb 761) Attenuates the Focal Cerebral Ischemic Injury-Induced Decrease in Astrocytic Phosphoprotein PEA-15 Levels. The American Journal of Chinese Medicine, vol. 39, No. 5, 971-979.… [cited by applicant]
Korn, Akira, et al. Focal Cortical Dysfunction and Blood-Brain Barrier Disruption in Patients With Postconcussion Syndrome. Journal of Clinical Neurophysiology. vol. 22, No. 1, Feb. 2005. pp. 1-9. [cited by applicant]
Kulhanek, V. Die Aldolaseaktivaet in Der Cerebrospinalen Fluessigkeit Nach Intrakranialen Verletzungen. Monatsschrift fur Unfallheilkunde, Versicherungs-, Versorgungs-und Verkehrsmedizin. 1963. 365-9. [cited by applicant]
Lee A, Lingwood BE, Bjorkman ST, Miller SM, Poronnik P, Barnett NL, Colditz P, Pow DV. 2010. Rapid loss of glutamine synthetase from astrocytes in response to hypoxia: implications for excitotoxicity. J Chem Neuroanat 3… [cited by applicant]
Linke S, Goertz P, Baader SL, Gieselmann V, Siebler M, Junghans U, Kappler J. 2006. Aldolase C/zebrin II is released to the extracellular space after stroke and inhibits the network activity of cortical neurons. Neuroch… [cited by applicant]
Lubieniecka JM, Streijger F, Lee JH, Stoynov N, Liu J, Mottus R, Pfeifer T, Kwon BK, Coorssen JR, Foster LJ and others. 2011. Biomarkers for severity of spinal cord injury in the cerebrospinal fluid of rats. PLoS One 6:… [cited by applicant]
Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M, Scalea T. 2008. Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma 65:778-82; discussion 782-4. [cited by applicant]
Martinez A, Carmona M, Portero-Otin M, Naudi A, Pamplona R, Ferrer I. 2008. Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage. J Neuropathol Exp Ne… [cited by applicant]
Mase M, Yamada K, Iwata A, Matsumoto T, Seiki K, Oda H, Urade Y. 1999. Acute and transient increase of lipocalin-type prostaglandin D synthase (beta-trace) level in cerebrospinal fluid of patients with aneurysmal subara… [cited by applicant]
Mase M, Yamada K, Shimazu N, Seiki K, Oda H, Nakau H, Inui T, Li W, Eguchi N, Urade Y. 2003. Lipocalin-type prostaglandin D synthase (beta-trace) in cerebrospinal fluid: a useful marker for the diagnosis of normal press… [cited by applicant]
Mathiisen TM, et al. The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia. Jul. 2010;58(9):1094-103. doi: 10.1002/glia.20990. [cited by applicant]
Mcmahon PJ, Panczykowski DM, Yue JK, Puccio AM, Inoue T, Sorani MD, Lingsma HF, Maas AI, Valadka AB, Yuh EL and others. 2015. Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomar… [cited by applicant]
Meco C, Oberascher G, Arrer E, Moser G, Albegger K. 2003. Beta-trace protein test: new guidelines for the reliable diagnosis of cerebrospinal fluid fistula. Otolaryngol Head Neck Surg 129:508-17. [cited by applicant]
Metting et al., “GFAP and S100B in the acute phase of mild traumatic brain injury”, Neurology 78, May 2012, pp. 1428-1433. [cited by applicant]
Yang et al., “Expressive proteomics profile changes of injured human brain cortex due to acute brain trauma”, Brain Injury, Sep. 2009, 23(10): 830-840. [cited by applicant]
Zhang et al., “Biomarkers of Traumatic Brain Injury and Their Relationship to Pathology”, Translational Research in Traumatic Brain Injury, 2015, pp. 263-276. [cited by applicant]